How Doctors Choose Cancer Treatment: A Personalized Approach to Care

No two cancer journeys are identical—and neither are treatment plans. When oncologists recommend a course of action, they weigh a complex matrix of medical, personal, and logistical factors. Understanding this decision-making framework empowers patients to engage as active partners in their care.

Core Medical Factors

Cancer Type and Stage

The primary driver of treatment options is the specific cancer diagnosis—its histological type (e.g., adenocarcinoma, squamous cell carcinoma), molecular subtype (hormone receptor status, HER2, genetic mutations), and stage (extent of spread). Early-stage solid tumors often favor surgery ± adjuvant therapy; advanced or metastatic disease typically involves systemic treatments (chemotherapy, targeted therapy, immunotherapy) ± radiation for symptom control.

Patient Health and Physiology

Age, performance status (ability to perform daily activities), organ function (heart, liver, kidney), and comorbid conditions (diabetes, heart disease, autoimmune disorders) critically influence what treatments a patient can safely tolerate. A frail 80-year-old with cardiac issues may not withstand aggressive chemotherapy that a fit 50-year-old could. Geriatric assessments and cardiopulmonary evaluations help quantify this.

Treatment Access and Expertise

Geographic and institutional realities matter. Academic medical centers offer clinical trials, multidisciplinary tumor boards, and sub-specialized surgeons. Community hospitals may have excellent standard-of-care capabilities but limited trial access. Rural patients may face travel barriers. Tele-oncology and satellite infusion centers are expanding options, but disparities persist.

Additional Decision-Making Factors

Tumor Characteristics

Size, location, and proximity to vital structures determine surgical feasibility and radiation planning. A tumor wrapped around a major blood vessel may be unresectable; one in the brainstem may limit radiation dose.

Biomarkers and Molecular Profiling

Genomic testing (e.g., FoundationOne, MSK-IMPACT, liquid biopsy) identifies actionable mutations (EGFR, ALK, BRAF, BRCA, MSI-H) that match patients to targeted therapies or immunotherapies. Biomarkers also predict chemotherapy benefit (e.g., Oncotype DX in breast cancer) or toxicity risk (DPYD variants for 5-FU).

Patient Values and Goals of Care

This is where the art of medicine meets the science. Some patients prioritize maximum survival time, accepting significant side effects. Others value quality of life, functional independence, or time at home over aggressive treatment with marginal benefit. Cultural, spiritual, and family considerations shape these preferences. There is no "right" choice—only the choice aligned with the patient's values.

The Collaborative Decision-Making Process

Modern oncology emphasizes shared decision-making. The physician provides expertise on evidence, risks, benefits, and uncertainties. The patient contributes their priorities, fears, support system, and life context. Together, they craft a plan that may include:

• Standard-of-care protocol
• Clinical trial enrollment
• Sequenced or combination modalities
• Palliative care integration from diagnosis
• Treatment breaks or dose modifications for quality of life

Second opinions are encouraged, especially for rare cancers or complex decisions. The best plan is one the patient understands, trusts, and feels ownership over—because adherence and resilience depend on that alignment.